Drug intelligence / Profile preview

LAS189962 + LAS189961

Development stage: Preclinical
Lead developer: Almirall
Administration: Topical

Overview

LAS189962 + LAS189961 is a combination investigational drug used for the treatment of superficial infected eczema and possibly other related dermatological conditions. The specific mechanism of action and details about the modality of each agent are not disclosed in available sources. The combination is under evaluation in clinical trials, likely targeting infection and inflammation in the context of skin diseases such as atopic dermatitis and eczema. Available data supports its use as a topical therapy for superficial skin infections.

Beyond the preview

Go deeper on LAS189962 + LAS189961.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LAS189962 + LAS189961.

Explore the full profile